NCT04937660Completed
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS)
Source: ClinicalTrials.gov · Last updated 10 Jun 2026
Brief summary (registry, in English)
The objective of this non-interventional multicenter study is to provide prospective, observational data on patients initiating treatment with palbociclib combination to contribute to the knowledge of HR+ HER2-metastatic/locally advanced Breast Cancer (BC) disease management, its treatment pattern, clinical outcomes and quality of life (QoL) in the routine clinical practice in Africa and Middle East countries .
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 185 (actual)
- First submitted
- 8 Jun 2021
- Start date
- 15 Jul 2021
- Primary completion date
- 29 Apr 2025
- Lead sponsor
- Pfizer
- Diseases
- Metastatic breast cancer
- NCT number
- NCT04937660
What you commit to
- Study type: Observational
- Participants enrolled: 185
- From 15 Jul 2021 to the primary completion date, 29 Apr 2025
- 12 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients on active treatment for malignancies other than metastatic/locally advanced BC at the time of enrollment
Other
- Patients participating in any interventional clinical trial
- Patients who are unable to understand the nature of the study and are unwilling to sign an informed consent
Who the study is looking for
- ≥18 years or older with diagnosis of adenocarcinoma of the breast with evidence of metastatic /locally advanced disease not amenable to treatment with curative intent.
- Documented HR+ (ER+ and/or PR+) tumor based on local standards
- Documented HER2- tumor based on local standards
- Will initiate treatment with palbociclib plus letrozole/aromatase inhibitor or palbociclib plus fulvestrant in line with the licensed indication(s), as first or second line therapy for metastatic/locally advanced BC at enrollment
- Patients who in the opinion of the investigator are willing and able to comply with regular clinic visits
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alexandria School of Medicine/Clinical Research Center CRC Coordinator of this site? Confirm its status | Alexandria | Egypt | Unknown status |
| Ain Shams University Hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
| Dar El Salam Oncology Hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
| National Cancer Institute Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
| King Hussein Cancer Center Coordinator of this site? Confirm its status | Amman | Jordan | Unknown status |
| Hôtel Dieu de France (HDF) Coordinator of this site? Confirm its status | Beirut | Lebanon | Unknown status |
| American University of Beirut Medical Center Coordinator of this site? Confirm its status | Beirut | Lebanon | Unknown status |
| Saint Joseph Hospital - Cancer Centers of Colorado Coordinator of this site? Confirm its status | Jdeidé - Metn | Lebanon | Unknown status |
| Hammoud Hospital University Medical Center (HHUMC) Coordinator of this site? Confirm its status | Sidon | Lebanon | Unknown status |
| Hamad Medical Corporation Coordinator of this site? Confirm its status | Doha | Qatar | Unknown status |
| King Fahad Specialist Hospital KFSH-Dammam Coordinator of this site? Confirm its status | Dammam | Saudi Arabia | Unknown status |
| National Guard Hospital, Riyadh Coordinator of this site? Confirm its status | Riyadh | Saudi Arabia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.